DAHANCA 19: a Randomized Study of the Importance of the EGFr-Inhibitor Zalutumumab for the Outcome After Primary Curative Radiotherapy for Squamous Cell Carcinoma of the Head and Neck

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2007
The purpose of this study is to determine whether the addition of the fully human EGFr antibody zalutumumab to primary curative radiotherapy increases locoregional control in Squamous Cell Carcinomas of the Head and Neck.
Epistemonikos ID: 95519eee872351c203455f9280c8071698b67fe8
First added on: May 04, 2024